What is the appropriate intravenous cyclophosphamide dose (mg/kg) for a patient, including adjustments for age and renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intravenous Cyclophosphamide Dosing

For intravenous cyclophosphamide in ANCA-associated vasculitis, use 15 mg/kg at weeks 0,2,4,7,10, and 13, with mandatory dose reductions for age and renal function: reduce to 12.5 mg/kg for patients ≥60 years, 10 mg/kg for patients ≥70 years, and reduce by an additional 2.5 mg/kg if GFR <30 ml/min/1.73 m² 1.

Standard Dosing Algorithm

The KDIGO 2024 guidelines provide explicit dosing:

  • Base dose: 15 mg/kg IV every 2-3 weeks
  • Schedule: Weeks 0,2,4,7,10,13 (with optional additional doses at weeks 16,19,21,24 if disease activity persists)
  • Maximum duration: 6 months 1

Age-Based Dose Reductions

Age significantly impacts cyclophosphamide tolerance and must be factored into dosing:

  • Age ≥60 years: Reduce to 12.5 mg/kg per dose
  • Age ≥70 years: Reduce to 10 mg/kg per dose 1

These reductions are critical because older patients have increased susceptibility to myelosuppression and infection. The 2024 KDIGO guidelines explicitly mandate these adjustments based on accumulated evidence of toxicity in elderly populations.

Renal Function Adjustments

For GFR <30 ml/min/1.73 m²: Reduce the dose by an additional 2.5 mg/kg beyond any age-based reductions 1.

This is particularly important because cyclophosphamide clearance decreases significantly with renal impairment 2. A 2002 pharmacokinetic study demonstrated that patients with creatinine clearance 10-24 mL/min had 40% reduction in cyclophosphamide clearance, resulting in 77% higher drug exposure (AUC 382 vs 216 μg·h/mL·g) 2.

Combined Adjustments Example

For a 72-year-old patient with GFR 25 ml/min/1.73 m²:

  • Start with base: 15 mg/kg
  • Age reduction (≥70 years): 10 mg/kg
  • Renal reduction (GFR <30): subtract 2.5 mg/kg
  • Final dose: 7.5 mg/kg per infusion

Critical Safety Considerations

Hydration is mandatory: Administer adequate fluids during or immediately after infusion to force diuresis and reduce hemorrhagic cystitis risk 3.

Monitoring requirements:

  • Do not administer if neutrophils ≤1,500/mm³ or platelets <50,000/mm³ 3
  • Expect nadir at weeks 1-2 with recovery by day 20 3
  • Monitor complete blood counts before each dose

Infection risk: Recent data from a 2024 Japanese cohort study suggests that doses exceeding 9 mg/kg may increase infection risk without improving efficacy. The study found that low-dose regimens (7.5-12.5 mg/kg) had lower infection rates (adjusted HR 0.20,95% CI 0.05-0.83) compared to conventional doses (>12.5 mg/kg), with similar relapse rates 4. This supports the guideline-recommended dose reductions for older patients and those with renal impairment.

Route Selection Considerations

The 2024 KDIGO guidelines favor IV cyclophosphamide for patients with 1:

  • Lower white blood cell counts
  • Prior moderate cumulative cyclophosphamide exposure
  • Ready access to infusion centers
  • Concerns about oral medication adherence

Oral cyclophosphamide (2 mg/kg/day for 3-6 months) remains an alternative but requires similar age and renal adjustments (reduce by 0.5 mg/kg/day for age ≥60, additional 0.5 mg/kg/day for age ≥70, and 0.5 mg/kg/day for GFR <30) 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.